- Shineco (SISI, Financial) acquires a 51% stake in InfiniClone for $19.9 million plus 3.45 million shares.
- InfiniClone holds 29 global patents spanning US, Europe, and Asia.
- InfiniClone's technology claims to enhance cell expansion efficiency by 3-10x and reduce costs by over 60%.
Shineco Inc. (SISI) has strategically expanded into the regenerative medicine sector by acquiring a controlling interest in InfiniClone, a Hong Kong-based biotechnology firm. The acquisition involves a cash payment of $19,895,600 and the issuance of 3,450,000 shares of Shineco common stock, marking a significant financial and strategic move for the company. This transaction is structured through Shineco’s subsidiary, Shineco Life Sciences Group Hong Kong Limited.
InfiniClone is renowned for its advanced stem cell technology and holds 29 global patents, which provide a strong intellectual property framework covering crucial markets including the United States, Europe, and Asia. The company’s core innovation lies in its ability to multiply cell expansion throughput by 3 to 10 times while concurrently reducing production costs by over 60% compared to conventional methodologies.
The acquisition signifies Shineco's entry into the high-value regenerative medicine market, reflecting its ambition to transition InfiniClone’s technologies from lab-scale to clinical applications. InfiniClone's technology is particularly promising in expediting treatment timelines for neurological conditions such as Parkinson’s, Alzheimer’s, and strokes, potentially reducing preparation periods from months to just weeks.
This acquisition is pivotal for Shineco as it diversifies its portfolio beyond diagnostic products, venturing into regenerative medicine, a field necessitating substantial clinical validation and regulatory approvals before reaching commercialization stages. Shineco's CEO, Jennifer Zhan, expressed optimism about solving critical healthcare challenges and enhancing patient care worldwide through this collaboration.
